lunes, 16 de noviembre de 2026

New organ donation rules are unfair to families A well-intended policy may put pressure on families to make decisions before they are ready

https://www.statnews.com/2026/11/13/organ-donation-policy-life-sustaining-treatment-brain-death/ By Tarvez TuckerNov. 13, 2026 Tucker is professor of neurology and neurocritical care at Oregon Health & Science University.

New addiction society guidance on medetomidine’s brutal withdrawal Severe withdrawal from the sedative may require an ICU stay, experts say

https://www.statnews.com/2026/11/13/medetomidine-withdrawal-asam-new-treatment-guidance/ By Theresa GaffneyNov. 13, 2026 Addiction Reporter Theresa Gaffney theresa.gaffney@statnews.com Theresa covers substance use and addiction and co-writes the Morning Rounds newsletter. You can reach Theresa on Signal at theresagaff.97.

FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics It’s a regulatory setback for Summit, though one that was not entirely unforeseen

https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/ By Adam FeuersteinNov. 15, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence The study results could change the way physicians treat certain patients with bladder cancer

https://www.statnews.com/2026/11/16/bladder-cancer-immunotherapy-reduced-tumor-recurrence-cg-oncology/ By Adam FeuersteinNov. 16, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

Helus’ psychedelic drug improved depression in study but faces safety questions Helus is one of a number of companies pursuing psychedelics for depression

https://www.statnews.com/2026/11/16/helus-psychedelics-depression-phase-3-trial/ By Elaine ChenNov. 16, 2026 National Biotech Reporter

Health and poverty: lessons from China The Lancet (++...)

Health and poverty: lessons from China The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)02186-0/fulltext?dgcid=raven_jbs_etoc_email The world has never been wealthier. Yet in 2025, an estimated 831 million people lived on less than US$3 per day. This stark disparity exposes a systemic failure to translate global prosperity into basic security and opportunity for all. As slowing economic growth and multiple crises, such as conflict and climate change, undermine the momentum of global poverty reduction, governments now face a pressing test: whether they will still find, reach, and protect those already furthest behind, or allow them to fall deeper into poverty. https://www.thelancet.com/journals/lancet/issue/vol408no10568/PIIS0140-6736(26)X2043-8

Coasting on artificial intelligence safety The Lancet Digital Health (++...)

Coasting on artificial intelligence safety The Lancet Digital Health https://www.thelancet.com/journals/landig/article/PIIS2589-7500(26)00149-4/fulltext?dgcid=raven_jbs_etoc_email Colluding on unsanctioned message boards and infiltrating a technology platform. Hacking the statistics portal of a health care scheme. Accessing and modifying personal data and business invoices. These are just a few examples from the past year of publicly reported systems breaches by artificial intelligence (AI) agents. Such reports have heightened some people's concerns that AI poses an existential threat, with others dismissing such concerns as marketing hype. What is not debatable is that AI agents are rapidly evolving, potentially beyond human containment. https://www.thelancet.com/journals/landig/issue/vol8no10/PIIS2589-7500(26)X2010-6